THE WHAT? Boston-based therapeutics company Indomo has secured US$25 million in funding to develop ClearPen™, an at-home investigational injectable therapy for inflammatory acne. The round was backed by Atomic, Foresite Capital, and Polaris Partners.
THE DETAILS ClearPen combines a microneedle self-injection device with triamcinolone acetonide, a corticosteroid used by dermatologists to treat acne lesions. The device aims to bring clinical-grade intralesional treatments into the home, addressing the limited access to in-office acne care.
Led by CEO Rick Bente and co-founder Jack Abraham, Indomo plans to use the funding to advance Phase 2 clinical trials and expand its microneedle delivery platform to other skin conditions.
THE WHY? The launch highlights the growing move toward self-administered dermatology treatments, as companies leverage biotech and medical device innovation to make specialist care more accessible.
Source: Webwire




































